<DOC>
	<DOCNO>NCT00771030</DOCNO>
	<brief_summary>This Phase 1b/2a study evaluate safety , tolerability PK PD AMG 827 administer multiple SC IV dose patient active rheumatoid arthritis combination stable dose DMARDs . Part A dose escalation ( assess safety &amp; tolerability ) , Part B dose expansion ( assess clinical efficacy ) high tolerate dose level AMG 827 Part A .</brief_summary>
	<brief_title>Multiple-dose Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Efficacy AMG 827 Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female 18 70 year age , inclusive time screen Diagnosed active RA ( class 13 ) least 6 month determine meet ACR 1987 revise classification criterion . Additional Inclusion Criteria Apply History evidence clinically significant disorder RA ( include limit cardiopulmonary , oncologic , renal , metabolic , hematologic psychiatric ) , condition disease , opinion Investigator Amgen physician would pose risk subject safety interfere study evaluation , procedures completion Uncontrolled , clinically significant systemic disease RA diabetes mellitus , liver disease , asthma , cardiovascular disease hypertension Malignancy within 5 year ( except successfully treat situ cervical cancer squamous basal cell carcinoma skin ) Presence serious chronic infection Subject ( male female ) willing use highly effective contraception , define double barrier method ( ie , spermicidal jelly condom , condom diaphragm ) treatment EOS Additional Exclusion Criteria Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>